Table 1: Selection, Design & Construction of HSV - based Oncolytic Viruses
Table 2: Selection, Design & Construction of Adenovirus - based Oncolytic Viruses
Table 3: Selection, Design & Construction of Vaccinia Virus - based Oncolytic Viruses
Table 4: Selection, Design & Construction of Vesicular Stomatitis Virus - based Oncolytic Viruses
Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses
Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses
Table 7: Current Company - Sponsored Clinical Trials of T - Vec
Table 8: Clinical Trials of ColoAd1
Table 9: Clinical Trials with JX - 594
Table 10: Clinical Trials with GL - ONC1
Table 11: Clinical Trials of CAVATAK (CVA21)
Table 12: Clinical Trials with MV - NIS
Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family
Table 14: Profile of Approved and Marketed Oncolytic Viruses
Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results
Table 16: Approved Indications of Immune Checkpoint Inhibitors
Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI)
Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI)
Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics
Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase
Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies
Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses
Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses
Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses
Table 25: First Generation Oncology Virus Companies and their Sources of Technology
Table 26: Second Generation Oncology Virus Companies and their Sources of Technology
Table 27: Third Generation Oncology Virus Companies and their Sources of Technology
Table 28:
Fourth Generation Oncology Virus Companies and their Sources of Technology
Table 29: Grants, Credits & Donations
Table 30: Financing by Venture Capital, Private Equity and Other Private Placements
Table 31: Collaboration & Licensing Agreements
Table 32: Companies
Listed on Stock Exchange & Offerings
Table 33: Mergers & Acquisitions